Literature DB >> 16939529

Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems.

Kirsten K Viktil1, Hege S Blix, Tron A Moger, Aasmund Reikvam.   

Abstract

AIM: To investigate whether polypharmacy defined as a definite number of drugs is a suitable indicator for describing the risk of occurrence of drug-related problems (DRPs) in a hospital setting.
METHODS: Patients admitted to six internal medicine and two rheumatology departments in five hospitals were consecutively included and followed during the hospital stay, with particular attention to medication and DRPs. Comparisons were made between patients admitted with five or more drugs and with less than five drugs. Clinical pharmacists assessed DRPs by reviewing medical records and by participating in multidisciplinary team discussions.
RESULTS: Of a total of 827 patients, 391 (47%) used five or more drugs on admission. Patients admitted with five or more and less than five drugs were prescribed the same number of drugs after admission: 4.1 vs. 3.9 drugs [P = 0.4, 95% confidence interval (CI) - 0.57, 0.23], respectively. The proportion of drugs used on admission which was associated with DRPs was similar in the patient group admitted with five or more drugs and in those admitted with less than five drugs. The number of DRPs per patient increased approximately linearly with the increase in number of drugs used; one unit increase in number of drugs yielded a 8.6% increase in the number of DRPs (95% CI 1.07, 1.10).
CONCLUSION: The number of DRPs per patient was linearly related to the number of drugs used on admission. To set a strict cut-off to identify polypharmacy and declare that using more than this number of drugs represents a potential risk for occurrence of DRPs, is of limited value when assessing DRPs in a clinical setting.

Entities:  

Mesh:

Year:  2006        PMID: 16939529      PMCID: PMC2000563          DOI: 10.1111/j.1365-2125.2006.02744.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  37 in total

1.  Polypharmacy and hospitalization among older home care patients.

Authors:  J H Flaherty; H M Perry; G S Lynchard; J E Morley
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2000-10       Impact factor: 6.053

2.  Polypharmacy among patients admitted to hospital with rheumatic diseases.

Authors:  K K Viktil; M Enstad; J Kutschera; L M Smedstad; J Schjøtt
Journal:  Pharm World Sci       Date:  2001-08

Review 3.  [Increased consumption of drugs among the elderly results in greater risk of problems].

Authors:  J Fastbom
Journal:  Lakartidningen       Date:  2001-04-04

Review 4.  Polypharmacy in the elderly: a literature review.

Authors:  Maryann M Fulton; Elizabeth Riley Allen
Journal:  J Am Acad Nurse Pract       Date:  2005-04

Review 5.  Healthy ageing: ageing safely.

Authors:  B M Buckley
Journal:  Eur Heart J       Date:  2001-11       Impact factor: 29.983

6.  Use of medications and polypharmacy are increasing among the elderly.

Authors:  Tarja Linjakumpu; Sirpa Hartikainen; Timo Klaukka; Juha Veijola; Sirkka-Liisa Kivelä; Raimo Isoaho
Journal:  J Clin Epidemiol       Date:  2002-08       Impact factor: 6.437

7.  Prescription drug use, diagnoses, and healthcare utilization among the elderly.

Authors:  T Jörgensen; S Johansson; A Kennerfalk; M A Wallander; K Svärdsudd
Journal:  Ann Pharmacother       Date:  2001-09       Impact factor: 3.154

8.  Pharmacotherapy consultation on polypharmacy patients in ambulatory care.

Authors:  J P Jameson; G R VanNoord
Journal:  Ann Pharmacother       Date:  2001 Jul-Aug       Impact factor: 3.154

9.  Geriatric drug therapy and healthcare utilization in the United kingdom.

Authors:  Anita Kennerfalk; Ana Ruigómez; Mari-Ann Wallander; Lars Wilhelmsen; Saga Johansson
Journal:  Ann Pharmacother       Date:  2002-05       Impact factor: 3.154

10.  Association between falls in elderly women and chronic diseases and drug use: cross sectional study.

Authors:  Debbie A Lawlor; Rita Patel; Shah Ebrahim
Journal:  BMJ       Date:  2003-09-27
View more
  166 in total

1.  Polypharmacy in attention deficit hyperactivity disorder treatment: current status, challenges and next steps.

Authors:  Regina Bussing; Almut G Winterstein
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

2.  Ten-year trends in hospital admissions for adverse drug reactions in England 1999-2009.

Authors:  Tai-Yin Wu; Min-Hua Jen; Alex Bottle; Mariam Molokhia; Paul Aylin; Derek Bell; Azeem Majeed
Journal:  J R Soc Med       Date:  2010-06       Impact factor: 5.344

Review 3.  Predicting risk of adverse drug reactions in older adults.

Authors:  Amanda Hanora Lavan; Paul Gallagher
Journal:  Ther Adv Drug Saf       Date:  2016-02

4.  Determinants of change in polypharmacy status in Switzerland: the population-based CoLaus study.

Authors:  Nazanin Abolhassani; Julien Castioni; Pedro Marques-Vidal; Peter Vollenweider; Gérard Waeber
Journal:  Eur J Clin Pharmacol       Date:  2017-06-21       Impact factor: 2.953

5.  Adverse drug reactions--no farewell to harms.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2007-02       Impact factor: 4.335

6.  Factors affecting family physicians' drug prescribing: a cross-sectional study in Khuzestan, Iran.

Authors:  Mohammad Arab; Amin Torabipour; Abbas Rahimifrooshani; Arash Rashidian; Nayeb Fadai; Roohollah Askari
Journal:  Int J Health Policy Manag       Date:  2014-10-20

7.  Relation Between Delirium and Anticholinergic Drug Burden in a Cohort of Hospitalized Older Patients: An Observational Study.

Authors:  Luca Pasina; Lorenzo Colzani; Laura Cortesi; Mauro Tettamanti; Antonella Zambon; Alessandro Nobili; Andrea Mazzone; Paolo Mazzola; Giorgio Annoni; Giuseppe Bellelli
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

8.  Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: be aware of atropinic and benzodiazepine drugs!

Authors:  François Montastruc; Virginie Gardette; Christelle Cantet; Antoine Piau; Maryse Lapeyre-Mestre; Bruno Vellas; Jean-Louis Montastruc; Sandrine Andrieu
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

9.  Epidemiology of Polypharmacy and Potential Drug-Drug Interactions Among Pediatric Patients in ICUs of U.S. Children's Hospitals.

Authors:  Dingwei Dai; James A Feinstein; Wynne Morrison; Athena F Zuppa; Chris Feudtner
Journal:  Pediatr Crit Care Med       Date:  2016-05       Impact factor: 3.624

10.  Geographical differences in the prevalence of chronic polypharmacy in older people: eleven years of the EPIFARM-Elderly Project.

Authors:  Carlotta Franchi; Massimo Cartabia; Paolo Risso; Daniela Mari; Mauro Tettamanti; Alberto Parabiaghi; Luca Pasina; Codjo Djignefa Djade; Ida Fortino; Angela Bortolotti; Luca Merlino; Alessandro Nobili
Journal:  Eur J Clin Pharmacol       Date:  2013-03-28       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.